TY - JOUR
T1 - Primary hyperparathyroidism in adults—(Part I) assessment and medical management
T2 - Position statement of the endocrine society of Australia, the Australian & New Zealand endocrine surgeons, and the Australian & New Zealand bone and mineral society
AU - Milat, Frances
AU - Ramchand, Sabashini K.
AU - Herath, Madhuni
AU - Gundara, Justin
AU - Harper, Simon
AU - Farrell, Stephen
AU - Girgis, Christian M.
AU - Clifton-Bligh, Roderick
AU - Schneider, Hans G.
AU - De Sousa, Sunita M.C.
AU - Gill, Anthony J.
AU - Serpell, Jonathan
AU - Taubman, Kim
AU - Christie, James
AU - Carroll, Richard W.
AU - Miller, Julie A.
AU - Grossmann, Mathis
N1 - Publisher Copyright:
© 2021 John Wiley & Sons Ltd.
PY - 2024/1
Y1 - 2024/1
N2 - Objective: To formulate clinical consensus recommendations on the presentation, assessment, and management of primary hyperparathyroidism (PHPT) in adults. Methods: Representatives from relevant Australian and New Zealand Societies used a systematic approach for adaptation of guidelines (ADAPTE) to derive an evidence-informed position statement addressing nine key questions. Results: PHPT is a biochemical diagnosis. Serum calcium should be measured in patients with suggestive symptoms, reduced bone mineral density or minimal trauma fractures, and in those with renal stones. Other indications are detailed in the manuscript. In patients with hypercalcaemia, intact parathyroid hormone, 25-hydroxy vitamin D, phosphate, and renal function should be measured. In established PHPT, assessment of bone mineral density, vertebral fractures, urinary tract calculi/nephrocalcinosis and quantification of urinary calcium excretion is warranted. Parathyroidectomy is the only definitive treatment and is warranted for all symptomatic patients and should be considered for asymptomatic patients without contraindications to surgery and with >10 years life expectancy. In patients who do not undergo surgery, we recommend annual evaluation for disease progression. Where the diagnosis is not clear or the risk-benefit ratio is not obvious, multidisciplinary discussion and formulation of a consensus management plan is appropriate. Genetic testing for familial hyperparathyroidism is recommended in selected patients. Conclusions: These clinical consensus recommendations were developed to provide clinicians with contemporary guidance on the assessment and management of PHPT in adults. It is anticipated that improved health outcomes for individuals and the population will be achieved at a decreased cost to the community.
AB - Objective: To formulate clinical consensus recommendations on the presentation, assessment, and management of primary hyperparathyroidism (PHPT) in adults. Methods: Representatives from relevant Australian and New Zealand Societies used a systematic approach for adaptation of guidelines (ADAPTE) to derive an evidence-informed position statement addressing nine key questions. Results: PHPT is a biochemical diagnosis. Serum calcium should be measured in patients with suggestive symptoms, reduced bone mineral density or minimal trauma fractures, and in those with renal stones. Other indications are detailed in the manuscript. In patients with hypercalcaemia, intact parathyroid hormone, 25-hydroxy vitamin D, phosphate, and renal function should be measured. In established PHPT, assessment of bone mineral density, vertebral fractures, urinary tract calculi/nephrocalcinosis and quantification of urinary calcium excretion is warranted. Parathyroidectomy is the only definitive treatment and is warranted for all symptomatic patients and should be considered for asymptomatic patients without contraindications to surgery and with >10 years life expectancy. In patients who do not undergo surgery, we recommend annual evaluation for disease progression. Where the diagnosis is not clear or the risk-benefit ratio is not obvious, multidisciplinary discussion and formulation of a consensus management plan is appropriate. Genetic testing for familial hyperparathyroidism is recommended in selected patients. Conclusions: These clinical consensus recommendations were developed to provide clinicians with contemporary guidance on the assessment and management of PHPT in adults. It is anticipated that improved health outcomes for individuals and the population will be achieved at a decreased cost to the community.
KW - asymptomatic hyperparathyroidism
KW - bone density
KW - hypercalcemia
KW - hyperparathyroidism
KW - parathyroid carcinoma
KW - parathyroid hormone
KW - parathyroidectomy
KW - renal calculi
UR - http://www.scopus.com/inward/record.url?scp=85121526146&partnerID=8YFLogxK
U2 - 10.1111/cen.14659
DO - 10.1111/cen.14659
M3 - Article
C2 - 34931708
AN - SCOPUS:85121526146
SN - 0300-0664
VL - 100
SP - 3
EP - 18
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 1
ER -